PUBLISHER: TechSci Research | PRODUCT CODE: 1879197
PUBLISHER: TechSci Research | PRODUCT CODE: 1879197
We offer 8 hour analyst time for an additional research. Please contact us for the details.
The Global Biotechnology Market, valued at USD 1.45 Trillion in 2024, is projected to experience a CAGR of 12.85% to reach USD 2.99 Trillion by 2030. Biotechnology encompasses the application of biological systems and processes to develop products and technologies that advance human health, agriculture, and industrial processes. Key drivers supporting the market's expansion include the increasing global prevalence of chronic and infectious diseases, necessitating advanced therapeutic and diagnostic solutions, alongside continuous advancements in genomics, molecular biology, and genetic engineering. The growing demand for personalized medicine also provides substantial impetus for market development.
| Market Overview | |
|---|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 1.45 Tillion |
| Market Size 2030 | USD 2.99 Trillion |
| CAGR 2025-2030 | 12.85% |
| Fastest Growing Segment | Biopharmaceuticals |
| Largest Market | North America |
Key Market Drivers
The biotechnology market is significantly propelled by breakthroughs in genetic engineering and gene editing technologies. These advancements, exemplified by tools such as CRISPR, enable precise modifications to genetic material, offering unprecedented potential for treating diseases at their root cause. This has led to a rapid expansion in therapeutic development, moving beyond conventional small molecules and biologics. This momentum is clearly reflected in regulatory milestones, as according to RegMedNet, May 2025, FDA-Approved Cell and Gene Therapies, the US Food and Drug Administration approved nine cell and gene therapy products in 2024, signaling a robust pipeline translating into tangible patient solutions.
Key Market Challenges
The substantial capital investment necessitated by extensive research and development activities presents a considerable impediment to the growth of the global biotechnology market. Developing innovative biological systems and processes demands significant, long-term financial commitments, often over many years before a product can reach commercialization. This inherent financial burden acts as a barrier, particularly for smaller biotechnology firms, limiting their capacity to pursue novel therapeutic and diagnostic solutions. For larger entities, the high costs can lead to a more conservative investment strategy, focusing resources on fewer, higher-probability projects, which can slow the overall pace of innovation and restrict the diversity of product pipelines across the industry.
Key Market Trends
The adoption of artificial intelligence in drug discovery and development is revolutionizing the pharmaceutical pipeline by enhancing the speed and efficiency of identifying drug candidates, optimizing lead compounds, and predicting clinical outcomes. This technology reduces the time and cost traditionally associated with bringing new therapies to market. For instance, according to the Massachusetts Biotechnology Council, Massachusetts-headquartered biopharma companies collectively received $7.89 billion in venture capital funding in 2024, reflecting substantial investment in innovation that includes AI-driven methodologies. Further illustrating this trend, Bexorg, Inc. announced the completion of a $23 million Series A financing in October 2025, specifically aimed at advancing its integrated AI and whole-human brain platform for central nervous system drug discovery and development.
In this report, the Global Biotechnology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies presents in the Global Biotechnology Market.
Global Biotechnology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: